search button
Open Access

Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms

  • Authors:
    • Li Ding
    • Jie Luo
    • Jing Ping Zhang
    • Ji Wang
    • Zhao Quan Li
    • Juan Huang
    • Li Chai
    • Jiao Mu
    • Beibei Zhao
    • Yi Rui Zhong
    • Lin Yi Zhang
    • Lin Liu

  • View Affiliations

  • Published online on: November 10, 2021     https://doi.org/10.3892/ol.2021.13128
  • Article Number: 10

  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sperm‑associated antigen 6 (SPAG6) is a newly identified cancer‑testis antigen that has been revealed to contribute to the occurrence and development of various types of human cancer, such as ovarian, bladder, breast and lung cancer. However, to the best of our knowledge, the expression levels of SPAG6 in breakpoint cluster region (BCR)/ABL1‑negative myeloproliferative neoplasms (MPNs) have not been investigated previously. Using reverse transcription‑quantitative PCR and different tissue staining techniques, the present study revealed that SPAG6 was expressed by MPN cells, both at the mRNA and protein levels, and that nucleated erythroid precursors and megakaryocytes expressed the highest levels of SPAG6. In addition, SPAG6, which is known as a microtubule‑associated protein, was found to exhibit nucleic, cytoplasmic or both cytoplasmic and nucleic subcellular localization patterns within the same patient or cell type; however, it did not always co‑localize with β‑tubulin. Furthermore, SPAG6 expression was revealed to be associated with fewer splenomegaly [P=0.015 for polycythemia vera (PV) and essential thrombocythemia (ET); and P=0.012 for primary myelofibrosis (PMF)] and myelofibrosis events (P=0.014 for PV and ET; and P=0.004 for PMF). In patients with PMF, upregulated expression levels of SPAG6 were also found to be associated with lower white blood cell counts (P=0.042) and lactate dehydrogenase levels (P=0.012), and higher hemoglobin levels (P=0.031) and platelet counts (P=0.025). In addition, the receiver operating characteristic curve analysis indicated that SPAG6 may be a potential biomarker for distinguishing MPN cases from healthy individuals. In conclusion, to the best of our knowledge, the present study is the first to report that aberrant SPAG6 expression may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative MPNs.
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ding L, Luo J, Zhang JP, Wang J, Li ZQ, Huang J, Chai L, Mu J, Zhao B, Zhong YR, Zhong YR, et al: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms. Oncol Lett 23: 10, 2022.
APA
Ding, L., Luo, J., Zhang, J.P., Wang, J., Li, Z.Q., Huang, J. ... Liu, L. (2022). Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms. Oncology Letters, 23, 10. https://doi.org/10.3892/ol.2021.13128
MLA
Ding, L., Luo, J., Zhang, J. P., Wang, J., Li, Z. Q., Huang, J., Chai, L., Mu, J., Zhao, B., Zhong, Y. R., Zhang, L. Y., Liu, L."Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms". Oncology Letters 23.1 (2022): 10.
Chicago
Ding, L., Luo, J., Zhang, J. P., Wang, J., Li, Z. Q., Huang, J., Chai, L., Mu, J., Zhao, B., Zhong, Y. R., Zhang, L. Y., Liu, L."Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms". Oncology Letters 23, no. 1 (2022): 10. https://doi.org/10.3892/ol.2021.13128